These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 26392071)

  • 1. Mapping the Pathways of Resistance to Targeted Therapies.
    Wood KC
    Cancer Res; 2015 Oct; 75(20):4247-51. PubMed ID: 26392071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of acquired resistance to targeted cancer therapies.
    Lackner MR; Wilson TR; Settleman J
    Future Oncol; 2012 Aug; 8(8):999-1014. PubMed ID: 22894672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Mechanism of Resistance to Chemotherapy in Gastric Cancers, the Role of Autophagy.
    Spirina LV; Avgustinovich AV; Afanas'ev SG; Cheremisina OV; Volkov MY; Choynzonov EL; Gorbunov AK; Usynin EA
    Curr Drug Targets; 2020; 21(7):713-721. PubMed ID: 31775598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic alterations as the basis for resistance to targeted therapies.
    Blair BG; Bardelli A; Park BH
    J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug resistance to targeted therapies: déjà vu all over again.
    Groenendijk FH; Bernards R
    Mol Oncol; 2014 Sep; 8(6):1067-83. PubMed ID: 24910388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticipating designer drug-resistant cancer cells.
    Frangione ML; Lockhart JH; Morton DT; Pava LM; Blanck G
    Drug Discov Today; 2015 Jul; 20(7):790-3. PubMed ID: 25697478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of targeted therapies in cancer: opportunities and challenges in the clinic.
    Santhosh S; Kumar P; Ramprasad V; Chaudhuri A
    Future Oncol; 2015; 11(2):279-93. PubMed ID: 25591839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Novel Mechanisms of Resistance to Investigational Molecularly Targeted Drugs].
    Noguchi K
    Yakugaku Zasshi; 2017; 137(2):151-160. PubMed ID: 28154324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.
    Tortora G; Bianco R; Daniele G; Ciardiello F; McCubrey JA; Ricciardi MR; Ciuffreda L; Cognetti F; Tafuri A; Milella M
    Drug Resist Updat; 2007 Jun; 10(3):81-100. PubMed ID: 17482503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics.
    Wijdeven RH; Pang B; Assaraf YG; Neefjes J
    Drug Resist Updat; 2016 Sep; 28():65-81. PubMed ID: 27620955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetics and oncology.
    Mummaneni P; Shord SS
    Pharmacotherapy; 2014 May; 34(5):495-505. PubMed ID: 24619798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The roadmap of TRAIL apoptotic pathway-targeted cancer therapies: What is next?
    Bellail AC; Hao C
    Expert Rev Anticancer Ther; 2012 May; 12(5):547-9. PubMed ID: 22594889
    [No Abstract]   [Full Text] [Related]  

  • 14. Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.
    Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
    Breast Cancer Res Treat; 2015 Oct; 153(3):493-505. PubMed ID: 26400847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNAs and cancer resistance: A new molecular plot.
    Fanini F; Fabbri M
    Clin Pharmacol Ther; 2016 May; 99(5):485-93. PubMed ID: 26875151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.
    Wilting RH; Dannenberg JH
    Drug Resist Updat; 2012; 15(1-2):21-38. PubMed ID: 22356866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding resistance to targeted cancer drugs through loss of function genetic screens.
    Berns K; Bernards R
    Drug Resist Updat; 2012 Oct; 15(5-6):268-75. PubMed ID: 23142522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addressing intra-tumoral heterogeneity and therapy resistance.
    Rybinski B; Yun K
    Oncotarget; 2016 Nov; 7(44):72322-72342. PubMed ID: 27608848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting autophagy to overcome drug resistance in cancer therapy.
    Kumar A; Singh UK; Chaudhary A
    Future Med Chem; 2015 Aug; 7(12):1535-42. PubMed ID: 26334206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mathematical modeling and computational prediction of cancer drug resistance.
    Sun X; Hu B
    Brief Bioinform; 2018 Nov; 19(6):1382-1399. PubMed ID: 28981626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.